Aurora Cannabis Inc(ACB) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.41 | Insider Own | 0.62% | Shs Outstand | 65.7M | Perf Week | 3.03% |
| Market Cap | 0.27B | Forward P/E | 54.34 | EPS next Y | 161.44% | Insider Trans | - | Shs Float | 65.3M | Perf Month | 1.24% |
| Enterprise Value | 0.18B | PEG | - | EPS next Q | -0.05 | Inst Own | 9.57% | Short Float | 12.54% | Perf Quarter | 44.17% |
| Income | -0.08B | P/S | 1.28 | EPS this Y | 86.29% | Inst Trans | 0.05% | Short Ratio | 6.38 | Perf Half Y | 24.01% |
| Sales | 0.21B | P/B | 0.7 | EPS next 5Y | - | ROA | -5.24% | Short Interest | 8.20M | Perf YTD | -3.32% |
| Book/sh | 5.87 | P/C | 2.55 | EPS past 3/5Y | 36.88% 45.34% | ROE | -7.1% | 52W High | -35.85% ($6.36) | Perf Year | -18.56% |
| Cash/sh | 1.6 | P/FCF | - | Sales past 3/5Y | 9.84% 3.95% | ROIC | -20.99% | 52W Low | 59.38% ($2.56) | Perf 3Y | -6.36% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -486.67% | Gross Margin | 9.77% | Volatility(W/M) | 3.74% 4.14% | Perf 5Y | -94.07% |
| Dividend TTM | - | EV/Sales | 0.85 | Sales Y/Y TTM | -18.23% | Oper. Margin | -56.85% | ATR (14) | 0.17 | Perf 10Y | -97.91% |
| Dividend Ex-Date | - | Quick Ratio | 2.8 | EPS Q/Q | 75.83% | Profit Margin | -38.37% | RSI (14) | 51.18 | Recom | 2.43 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.36 | Sales Q/Q | -31.07% | SMA20 | -1.71% ($4.15) | Beta | 0.67 | Target Price | $4.03 |
| Payout | - | Debt/Eq | 0.04 | Earnings | 2026/8/5 | SMA50 | 1.08% ($4.04) | Rel Volume | 0.43 | Prev Close | $4.15 |
| Employees | 1028 | LT Debt/Eq | 0.03 | EPS/Sales Surpr. | 61.54% 0.36% | SMA200 | 15.16% ($3.54) | Avg Volume(3M) | 1.28M | Price | $4.08 |
| IPO | 2014/7/11 | Option/Short | Yes/Yes | Trades | 1764 | Volume | 554,427 | Change | -1.69% |
🌿 Headquartered in Alberta, Canada, this is a global medical and recreational cannabis cultivation and distribution company. Established in 2013, it operates a vertically integrated business structure spanning from cultivation to derivative product development and distribution, and runs operations across multiple countries in the global medical cannabis market.
Over the past 1 year, roughly in the middle
36% below its 1-year high.
Traded less than usual. That is 43% of its average volume.
ACB has a sound balance sheet but weak earning power
Of every $100 in sales, $56.85 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +86.3% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $128. Peers typically go for $212.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -94.1%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 9.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #47 of 83 in the industry
Based on market cap of $268M.
ANIK#44 Anika Therapeutics Inc $288M PER - 
CGC#45 Canopy Growth Corp $282M PER - 
BIOA#46 BioAge Labs Inc $273M PER - ACB#47 Aurora Cannabis Inc $268M PER - 
LFCR#48 Lifecore Biomedical Inc $247M PER - 
FAQ
What kind of company is ACB?
ACB belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of ACB?
The market cap of ACB is approximately $268M, ranking 3,777 within its sector.
What is the 52-week high and low for ACB?
ACB has recorded a 52-week high of $6.36 and a low of $2.56.
